Positions

Investigator On

  • NMTRC014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)  awarded by SPECTRUM HEALTH 2017 - 2022
  • A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2022
  • PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma  awarded by SPECTRUM HEALTH 2017 - 2022
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2022
  • Private Grant  awarded by Bayer AG 2018 - 2022
  • Reduced Burden Of Oncology Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents, and Young Adults with CD20+ Mature B-Cell Lymphoma  awarded by NEW YORK MEDICAL COLLEGE 2017 - 2022
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2022
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2016 - 2021
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP 2015 - 2020
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2015 - 2020
  • Cookies for Kids' Cancer Phase 1 Supplemental  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2020
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2020
  • NIH COG Phase I Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • Transforming Pediatric Oncology Healthcare Through Family Navigation  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2017 - 2019
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia  awarded by Duke University 2017 - 2019
  • Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • CTSU: Phase ll Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2018
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018
  • ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2018
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2018
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2018
  • ALTE11C2 Study - Health Effects after Antracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2017
  • ALTE11C2 Study – Health Effects After Antracycline and Radiation Therapy (HEART) – Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2017
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2017
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2017
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee 2015 - 2016
  • CCOP Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2015
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2015
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2015
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2014
  • AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD  awarded by CHILDREN'S ONCOLOGY GROUP 2014
  • COG Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2014
  • Teaching Activities

  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2018) 2018
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2018) 2018
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2018) 2018
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2018) 2018
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2018) 2018
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2018) 2018
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2017) 2017
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2017) 2017
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2017) 2017
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2017) 2017
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2017) 2017
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2017) 2017
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2017) 2017
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016) 2016
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016) 2016
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016) 2016
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016) 2016
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2016) 2016
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2015) 2015
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2015) 2015
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2014) 2014
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2013) 2013
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Fall Term 2011) 2011
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Fall Term 2010) 2010
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Fall Term 2009) 2009
  • PCL2225 - HEMATOLOGY / ONCOLOGY (Fall Term 2008) 2008
  • Education And Training

    Full Name

  • Kimberly Whelan
  • Blazerid

  • kifowler